trial · primary record
Enzalutamide
Hormone Sensitive Prostate Cancer
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 1068 |
| Primary completion | 2027-07-30 |
| Primary endpoint | Metastasis-free Survival (MFS) Compared Between Enzalutamide Plus Leuprolide and Placebo Plus Leuprolide |
| Registry ID | NCT02319837 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:04.982Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02319837
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.